The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).
Kathryn Maree Field
Other Remuneration - Roche
John Simes
No relevant relationships to disclose
Helen Wheeler
No relevant relationships to disclose
Elizabeth J. Hovey
Consultant or Advisory Role - Roche
Anna K. Nowak
No relevant relationships to disclose
Lawrence Cher
No relevant relationships to disclose
Chris Brown
No relevant relationships to disclose
Ann Livingstone
No relevant relationships to disclose
Kate Sawkins
No relevant relationships to disclose
Mark Rosenthal
Consultant or Advisory Role - Roche